Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211389 · ClinicalTrials.gov registry record · Phase 3
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
A Phase 3 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
NCT04211389 is a Phase 3 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 442 participants.
The verdict
NCT04211389, a Phase 3 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day for 56 days by subjects with chronic plaque psoriasis
Interventions
- DRUG ARQ-151 vehicle cream
- DRUG ARQ-151 0.3% cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2020-11-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04211389
The ClinicalTrials.gov registry entry for NCT04211389 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ARQ-151 vehicle cream is the first listed.
NCT04211389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04211389 about?
NCT04211389 is a clinical study titled "Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis". This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day for 56 days by subjects with chronic plaque psoriasis
What is the current status of trial NCT04211389?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2019-12-17. Estimated completion is 2020-11-23.
What interventions are being tested in trial NCT04211389?
The interventions under investigation include: ARQ-151 vehicle cream (DRUG), ARQ-151 0.3% cream (DRUG).
Who is sponsoring clinical trial NCT04211389?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.